<DOC>
	<DOCNO>NCT00951106</DOCNO>
	<brief_summary>The purpose study determine efficacy pyrimethamine/sulfdoxine ( Fansidar® ) treatment uncomplicated falciparum malaria Peruvian Amazon . Reports mid 1990s indicated Fansidar failing cure patient confirm falciparum malaria . The study design base accept WHO parasitological clinical outcome determine overall efficacy Fansider inform Peruvian National Malaria Control authority continue wisdom recommend Fansidar first line treatment uncomplicated falciparum malaria Peruvian Amazon .</brief_summary>
	<brief_title>Therapeutic Efficacy Study Pyrimethamine/Sulfdoxine ( Fansidar® ) Treatment Uncomplicated Falciparum Malaria Peruvian Amazon</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<criteria>Pf monoinfection asexual form Parasite density great 500 per mcl le 200 parasite per oil immersion field ( MINSA quantification `` 4 plus '' ) Age &gt; 6 month Temperature great 38C ( 101F ) Available willing return followup Presence follow `` danger '' sign symptom suggestive severe malaria Not able drink breastfeed Repeated vomit ( unable keep anything ) Convulsions present illness Lethargic unconscious state Unable sit stand Respiratory distress Jaundice ( observation ) dark urine ( history ) Severe anemia ( Hemoglobin &lt; 5 g/dl ) Hypotension ( systolic BP &lt; 80 mm Hg adult &lt; 50 mm Hg child age 5 Presence another significant illness chronic disease Known pregnancy ( history ) History hypersensitivity medication use test</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Peru</keyword>
	<keyword>Sulfadoxine-pyrimethamine</keyword>
	<keyword>Drug resistance</keyword>
</DOC>